Relay Therapeutics (RLAY) Income Statement: Revenue & Earnings

Relay Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Relay Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	10.01	25.55	1.38	3.03	82.65
Cost of Revenue	0.00	326.39	243.01	169.39	96.59
Gross Profit	10.01	-300.84	-241.62	3.03	82.65
Operating Expenses
Research & Development	319.09	330.02	246.36	172.65	99.86
Selling, General & Administrative	76.59	78.58	69.33	57.39	38.59
Operating Expenses	382.48	78.58	69.33	230.04	138.45
Operating Income	-372.47	-379.42	-310.95	-227.01	-55.80
Other Income/Expense
Interest Income	34.75	31.05	8.79	0.83	3.40
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	34.76	-0.02	-0.02	-137.70	0.02
Income
Income Before Tax	-337.71	-341.97	-290.51	-363.87	-52.41
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-337.71	-341.97	-290.51	-363.87	-52.41
Net Income - Continuous Operations	-337.71	-341.97	-290.51	-363.87	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-380.21	-374.15	-306.82	-223.08	-52.25
EBIT	-337.71	-379.42	-310.95	-227.01	-55.80
Depreciation & Amortization	5.46	5.27	4.13	3.93	3.50
Earnings Per Share
Basic EPS	-2.00	-3.00	-3.00	-4.00	-5.00
Diluted EPS	-2.00	-3.00	-3.00	-4.00	-5.00
Basic Shares Outstanding	142.87	122.58	112.23	95.14	42.62
Diluted Shares Outstanding	142.87	122.58	112.23	95.14	42.62